Medicine on the Move: Incorporating Novel JAK Inhibitors and Other Emerging Therapies into Higher-Risk Myelofibrosis Treatment
1.50 CME CE: Many patients with myelofibrosis are unresponsive or intolerant to ruxolitinib, learn about new JAK inhibitor therapies that provide options for these patients. Exp 2/24/24